Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer Please visit their website for more information.
*Proprietary Buy Sell Volume Indicator
| Revenue: $11.44B |
| Revenue Growth (YOY): 20.43% |
| Profit (% of Rev): 81.02% |
| Income (% of Rev): 8.48% |
| Income Growth (YOY): -1790.42% |
| Operating Income: $4.43B |
| Operating Cash Flow: $3.71B |
| Operating Cash Flow Growth (YoY): 69.53% |
| Annual Dividend Yield: 0.15% |
| Total Assets: $75.61B |
| Total Liabilities: $61.29B |
| Cash & Equivalent: $3.37B |
| Total Debt: $31.12B |
| Debt/Equity: 2.19 |
| Quick Ratio: 0.97 |
| Current Ratio: 1.27 |
| Price/Book: 56.06 |
| Price/Earnings: 205.67 |
| EBITDA: $2.25B |
| EPS: 1.08 |
Our proprietary analysis employs a weighted average approach integrating both functional and technical parameters, tailored to the sector, industry, and microeconomic factors. This methodology assigns dynamic weights to the parameters, with a focus on recent trends, ensuring a nuanced evaluation for informed investment decisions. Considering all the above parameters, in addition to some of the derived parameters of the stock in conjunction with its sector and macroeconomic conditions, our proprietary Weighted Average AI model gives a rank of Buy.
TheoryofStocks is not registered as an investment advisor with any regulatory authority. The information provided on this Website is for educational purposes only and should not be construed as financial or investment advice. By continuing to use this site, you are agreeing to the Terms of Use and Privacy Policy. Please read our Disclaimer.
Contact @ support@theoryofstocks.com
© 2024 Stock Articles. All rights reserved.